- Home
- » Tags
- » Cariprazine
Top View
- The Continuum Hypothesis
- Neurotransmitters in Health and Disease
- Utah Medicaid Dur Report December 2020 Newer Oral
- Clinical Policy: Aripiprazole Long-Acting Injections (Abilify
- Psychotropic Drug Information for Children and Adolescents
- Parenteral Antipsychotics
- Current Concepts and Treatments of Schizophrenia
- Antipsychotic Update
- Psychotropic Monitoring Guidelines (PDF)
- Atypical Antipsychotics NOTICE
- Strategies for Managing Medication-Induced Hyperprolactinemia
- Assessment Report
- Abilify Maintena, Aristada) Reference Number: ERX.SPA.177 Effective Date: 09.05.17 Last Review Date: 11.17 Revision Log
- Cariprazine for Schizophrenia
- Novel Antipsychotic Drugs Approved in 2015: Brexpiprazole, Cariprazine
- A Concise Guide to Monoamine Oxidase Inhibitors: How to Avoid Drug Interactions
- Akathisia As an Extrapyramidal Side Effect of Fluoxetine
- Clinically Relevant Interactions Between Atypical Antipsychotics and Anti-Infective Agents
- Vraylar (Cariprazine) P&T Approval Date 4/2016, 5/2017, 5/2018, 5/2019, 5/2020, 6/2021 Effective Date 9/1/2021; Oxford Only: 9/1/2021
- A Clinically Oriented Review of Lurasidone, Brexpiprazole, Cariprazine and Lumateperone
- Graylands Hospital Drug Bulletin Brexpiprazole
- Finding Peace of Mind Treatment Strategies for Depression
- UPDATE on NEURO/PSYCH MEDICATIONS Steve Williams, Pharm.D
- Alteration of Monoaminergic Neuronal Firing by Acute Administration Of
- Second-Generation Antipsychotic Tip Sheet
- Utah Medicaid Pharmacy & Therapeutics Drug Class Review
- Regulatory Approval for Marketing Cariprazine (MP-214) for the Treatment of Schizophrenia
- The Safety and Tolerability of Cariprazine in Long-Term Treatment of Schizophrenia: a Post Hoc Pooled Analysis Henry A
- Section I: Atypical Antipsychotics 12/2020
- Effect on Body Weight and Adipose Tissue by Cariprazine
- Major Depressive Disorder (MDD) and Schizophrenia
- Please List Current Or Past Medications, Doses, and Frequency Taken: MEDICATION DOSE (MG.) FREQUENCY PAST / PRESENT 1 2 3 4 5 6
- New Drug Evaluation Monograph Template
- Antipsychotics
- Black-Box Warnings for First-Generation Antipsychotics
- Weight Gain, Sedation Typical Antipsychotics
- Pharmacogenomic Biomarkers and Their Applications in Psychiatry
- Central Nervous System
- VRAYLAR Safely and Effectively
- Antipsychotics, Dopamine, and Pain
- Drug Pipeline Update
- Tricyclic Antidepressants
- Antipsychotics Quick Reference Guide (PDF)
- VRAYLAR (4) These Highlights Do Not Include All the Information Needed to Use VRAYLAR Safely and Effectively
- Advances in Psychopharamacology: 2011-2015
- Medications to Avoid
- Atypical Antipsychotics Comparison Guide
- Definition of Treatment-Resistant Depression in the Medicare Population
- Investigating the Potential Role of Serotonin-2B Receptor Antagonism in the Neuronal Actions of Adjunctive Aripiprazole
- Psychopharmacology: the Basics and Beyond
- Schizophrenia
- Multi-Target Approach for Drug Discovery Against Schizophrenia
- Cariprazine (Vraylar) for Schizophrenia in Adults
- Aripiprazole Lauroxil, a Novel Injectable Long-Acting Antipsychotic Treatment for Adults with Schizophrenia: a Comprehensive Review